tbuckley/cabot-search huggingface dataset:
HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy
Authors: Lung‐Yi Mak, Gavin Cloherty, Danny Ka‐Ho Wong, Jeffrey Gersch, Wai‐Kay Seto, James Fung, Man‐Fung Yuen
Journal: Hepatology (2020)

Large-scale comprehensive studies on HBV RNA in chronic hepatitis B are lacking. We aimed to study the HBV RNA profile and its correlation with other viral markers in patients with chronic hepatitis B who are treatment-naïve and patients receiving nucleos(t)ide analogues (NA).Biomarkers, including HBV RNA and hepatitis B core-related antigen (HBcrAg), were measured in 388 patients. Of these, 246 were treatment-naïve and were categorized into HBeAg-positive chronic infection (n = 41), HBeAg-positive chronic hepatitis (n = 81), HBeAg-negative chronic infection (n = 39), HBeAg-negative chronic hepatitis (n = 66), and HBsAg seroclearance (n = 19). These biomarkers were also measured in 142 patients who were NA-treated receiving tenofovir or entecavir at baseline, week 48, and week 96. The pattern of serum HBV RNA levels mirrored HBV DNA (1-2 logs higher than HBV RNA) and HBcrAg in patients who were treatment-naïve. HBV RNA correlated best with HBcrAg (r = 0.84) and to a lesser extent with HBV DNA (r = 0.737) (both P < 0.001). In patients with HBsAg seroclearance, 15.8% and 15.8% had detectable serum HBV RNA and HBcrAg, respectively. NA treatment reduced serum HBV RNA by 1.46 logs and 1.77 logs at weeks 48 and 96, respectively. At week 96 of NA therapy, only 19.1% patients who were tenofovir-treated and 25.7% patients who were entecavir-treated had unquantifiable HBV RNA (P > 0.05). In patients who were treated and had undetectable HBV DNA, 77.5% and 30% had quantifiable HBV RNA and HBcrAg, respectively.HBV RNA showed distinct and corresponding profiles in patients with HBV in different disease phases. HBV RNA and HBcrAg could be used to monitor residual transcriptional activities in patients with HBsAg seroclearance. NA led to reduction of serum HBV RNA. Monitoring of viral activities can still be achieved in patients with undetectable HBV DNA by serum HBV RNA.
Real-World Treatment Patterns and Healthcare Resource Utilization (HRU) of Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
Authors: Wendy Y Cheng, Sujata P. Sarda, Nikita Mody-Patel, Sangeeta Krishnan, Mihran Yenikomshian, Patrick J. Scoble, Malena Mahendran, Dominique Lejeune, Louise Yu, Mei Sheng Duh
Journal: Blood (2020)
TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment
Authors: Jiye Liu, Teru Hideshima, Lijie Xing, Su Wang, Daisuke Ogiya, Mehmet K. Samur, Nikhil C. Munshi, Paul G. Richardson, Kenneth Wen, Yu-Tzu Tai, Yong Cang, Kenneth Anderson
Journal: Blood (2020)
Peripheral Oxygen Saturation in Older Persons Wearing Nonmedical Face Masks in Community Settings
Authors: Noel C. Chan, Karen Li, Jack Hirsh
Journal: JAMA (2020)

This study describes changes in portable oximeter–measured peripheral oxygen saturation (Spo2 or O2sat) in older adults before, during, and after wearing a 3-layer plane-shaped disposable nonmedical face mask widely used to protect against COVID-19.
Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT)
Authors: Rashmi Kanagal-Shamanna, Shruti Rao, Panieh Terraf, Gordana Raca, Jason Saliba, Arpad Danos, Coumarane Mani, Heather Williams, Nan Jiang, Kevin C Vavra, Liying Zhang, Zonggao Shi, Peng Li, Yuwen Li, Madhu Michael Ouseph, Ella R Thompson, Yiming Zhong, Nicole Hinceman, Rong He, Kilannin Krysiak, Alex Wagner, Matthew McCoy, Mariam T Matthew, Kristin Deeb, Fengli Zhang, Jie Liu, David S. Viswanatha, Piers Blombery, David Wu, Shashikant Kulkarni, Subha Madhavan, Xinjie Xu
Journal: Blood (2020)
Remission in Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide (varitrinox) As the First Line in Colombia
Authors: Gustavo Milone, Samuel Sarmiento Doncel, Carol Agudelo Rico, Fabiola Vizcarra Reyes, Gina Alejandra Diaz Mosquera, Juan Guillermo Duque Ortega, Javier Mauricio Cortes Bernal, Francisco Javier Meza Cadavid
Journal: Blood (2020)
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review
Authors: Sera Whitelaw, Kristen Sullivan, Yousif Eliya, Mohammad Alruwayeh, Lehana Thabane, Clyde W. Yancy, Roxana Mehran, Mamas A. Mamas, Harriette G.C. Van Spall
Journal: European Journal of Heart Failure (2020)
Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
Authors: Kelly S. Chien, Gautam Borthakur, Kiran Naqvi, Naval Daver, Guillermo Montalban Bravo, Jorge E. Cortes, Courtney D. DiNardo, Elias Jabbour, Yesid Alvarado, Michael Andreeff, Prithviraj Bose, Nitin Jain, Kimberly Sheppard, Cheri Klingner-Winton, Sherry A. Pierce, Xiao Qin Dong, Kelly A. Soltysiak, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2020)
<i>Genetic Manipulation Resulting in Decreased Donor Chondroitin</i> <i>sulfate</i> <i>Synthesis Mitigates Gvhd Following Allogeneic Hematopoietic Cell Transplantation in a Murine Model.</i>
Authors: Suguru Tamura, Takashi Ushiki, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Kyoko Fuse, Yasuhiko Shibasaki, Miwako Narita, Michihiro Igarashi, Hirohito Sone, Masayoshi Masuko
Journal: Blood (2020)
Electronic cigarettes for smoking cessation: an opportunity to readdress smoking cessation treatment
Authors: Paraskevi A. Katsaounou
Journal: European Respiratory Journal (2020)

<b>The effectiveness of e-cigarettes for smoking cessation still lacks a valid endorsement. It is timely to treat the chronic disease of nicotine addiction safely and effectively, by incorporating smoking cessation guidelines to our everyday practice.</b>https://bit.ly/3gUjGRM
Abstract 424: Loss of Sirt2 Protects Against Pressure Overload- and Ischemic Reperfusion Injury-induced Cardiac Dysfunction
Authors: Teruki Sato, Xiaoyan Yan, Hsiang-Chun Chang, Chen Chunlei, Jason S Shapiro, Hossein Ardehali
Journal: Circulation Research (2020)

Introduction: Sirtuins are NAD+ dependent deacetylases and critical regulators of energy metabolism and response to oxidative stress. Sirtuin2 (SIRT2) is a cytoplasmic member of the sirtuin family, and has been shown to regulate cellular iron homeostasis through deacetylation of nuclear factor erythroid-derived 2-related factor 2 (NRF2). However, whether SIRT2-NRF2 pathway is involved in the development of heart failure remains unknown. Methods and results: To investigate the functional role of SIRT2 in the response to cardiac stress, SIRT2 knockout (KO) mice and their littermate controls were subjected to pressure overload by transverse aortic constriction (TAC). SIRT2 KO had normal appearance and cardiovascular parameters at baseline. However, in response to TAC, Sirt2 -/- mice displayed resistance to the pathological hypertrophic response, whereas wild type (WT) mice developed cardiac hypertrophy and heart failure. In addition, SIRT2 KO mice displayed less cardiac damage after /reperfusion injury. SIRT2 knockdown in neonatal rat cardiomyocytes (NRCM) reduced reactive oxygen species (ROS) production and cell death after H2O2 treatment. Since cellular oxidative stress is one of major contributor of cardiac dysfunction caused by both I/R injury and pressure overload, we examined whether NRF2 is associated with SIRT2-mediated cardiac response to oxidative stress. Levels of NRF2 was upregulated in NRCM with SIRT2 knockdown and treated with H2O2 compared to wild type (WT) cells. Moreover, NRF2 is translocated into the nucleus and its anti-oxidant target proteins are upregulated in NRCM with SIRT2 knockdown. SIRT2 was also found to bind and deacetylate NRF2 directly as determined by co-immunoprecipitation studies. This led to a reduction of its nuclear translocation and transcriptional activity. Finally, knockdown of both SIRT2 and NRF2 diminished the effects of SIRT2 knockdown on ROS production and cellular damage. Conclusion: These results indicate that SIRT2 contributes to pressure overload and I/R injury induced heart impairment in mice, and promotes oxidative stress injury in cardiomyocytes via deacetylating NRF2 and altering its activity.
Cord Blood T Regulatory Cells Can Dampen Cytokine Release Syndrome and Improve on Target Efficacy of CD19 CAR T Cells
Authors: Ke Zeng, Li Li, Meixian Huang, Mi-Ae Lyu, Mitsutaka Nishimoto, Hongbing Ma, Tara Sadeghi, Loretta J. Nastoupil, Krina K. Patel, Sairah Ahmed, Simrit Parmar
Journal: Blood (2020)
Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm
Authors: Richard Ferraro, Jacqueline M. Latina, Abdulhamied Alfaddagh, Erin D. Michos, Michael J. Blaha, Steven R. Jones, Garima Sharma, Jeffrey C. Trost, William E. Boden, William S. Weintraub, João A.C. Lima, Roger S. Blumenthal, Valentin Fuster, Armin Arbab-Zadeh
Journal: Journal of the American College of Cardiology (2020)
Interactions of Key Hematological Parameters with Red Cell Distribution Width (RDW) Are Associated with Incidence of Thromboembolic Events (TEs) in Polycythemia Vera (PV) Patients: A Machine Learning Study (PV-AIM)
Authors: Srdan Verstovsek, Valerio De Stefano, Florian H. Heidel, Mike Zuurman, Michael Zaiac, Kenneth Bryan, Brian Buckley, Ashwini Mathur, Mara Morelli, Erwan Bigan, Michael Ruhl, Christoph Meier, Magali Beffy, Jean-Jacques Kiladjian
Journal: Blood (2020)
High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer’s and Non-Alzheimer’s Disease Tauopathies
Authors: Kenji Tagai, Maiko Ono, Manabu Kubota, Soichiro Kitamura, Keisuke Takahata, Chie Seki, Yuhei Takado, Hitoshi Shinotoh, Yasunori Sano, Yasuharu Yamamoto, Kiwamu Matsuoka, Hiroyuki Takuwa, Masafumi Shimojo, Manami Takahashi, Kazunori Kawamura, Tatsuya Kikuchi, Maki Okada, Haruhiko Akiyama, Hisaomi Suzuki, Mitsumoto Onaya, Takahiro Takeda, Kimihito Arai, Nobutaka Arai, Nobuyuki Araki, Yuko Saito, John Q. Trojanowski, Virginia M.Y. Lee, Sushil K. Mishra, Yoshiki Yamaguchi, Yasuyuki Kimura, Masanori Ichise, Yutaka Tomita, Ming-Rong Zhang, Tetsuya Suhara, Masahiro Shigeta, Naruhiko Sahara, Makoto Higuchi, Hitoshi Shimada
Journal: Neuron (2020)
Assessment of Red Blood Cell-Mediated Microvascular Occlusion in Sickle Cell Disease By a Novel Electrical Impedance-Based Microfluidic Device
Authors: Yuncheng Man, Debnath Maji, Ran An, Sanjay P Ahuja, Jane A. Little, Pedram Mohseni, Michael A Suster, Umut A. Gurkan
Journal: Blood (2020)
The Role of Upfront Autologous Hematopoietic Cell Transplantation in the Treatment of Mantle Cell Lymphoma, a Population Based Study Using the National Cancer Data Base (NCDB)
Authors: Yazeed Sawalha, Tomas Radivoyevitch, Katherine Tullio, Robert M. Dean, Brad Pohlman, Brian T. Hill, Matt Kalaycio, Navneet S. Majhail, Deepa Jagadeesh
Journal: Blood (2017)
Ibrutinib in Combination with R-Gemox-D in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase II Clinical Trial of the Geltamo Group
Authors: Beatriz Rey Búa, Ana Jiménez Ubieto, Jose Javier Sanchez Blanco, Pau Abrisqueta, Antonio Gutierrez, Angel Ramirez Payer, Eva Giné, Izaskun Cebeiro, Maria Jose Terol, Fatima De la Cruz, Rafael Andreu, María José Ramírez Sánchez, Adolfo de la Fuente, Ma Cruz Viguria, Maria Jesús Peñarrubia, Carlos Grande, Dolores Caballero, Alejandro Martin Garcia-Sancho
Journal: Blood (2020)
Loss of H3K27 Methylation Identifies Poor Outcome in Adult-Onset Acute Myeloid Leukemia
Authors: Anneke D. van Dijk, Fieke W Hoff, Yihua Qiu, Eveline S. de Bont, Sophia W.M. Bruggeman, Terzah M Horton, Steven M. Kornblau
Journal: Blood (2020)
Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation
Authors: Kevin H Kensler, Claire H Pernar, Brandon A Mahal, Paul L Nguyen, Quoc-Dien Trinh, Adam S Kibel, Timothy R Rebbeck
Journal: JNCI Journal of the National Cancer Institute (2020)

The 2012 US Preventive Services Task Force recommendation against routine prostate-specific antigen (PSA) testing led to a decrease in prostate cancer screening, but the heterogeneity of its impact by race and ethnicity remains unclear.The proportion of 40- to 74-year-old men who self-reported receiving a routine PSA test in the past year was estimated in the Behavioral Risk Factor Surveillance System (2012-2018). Odds ratios (ORs) of undergoing screening by race and ethnicity were estimated, adjusting for healthcare-related factors. Prostate cancer incidence rates and rate ratios (IRRs) by race and ethnicity were estimated using Surveillance, Epidemiology, and End Results registry data (2004-2017).PSA testing frequencies were 32.3% (95% confidence interval [CI] = 31.7% to 32.8%) among non-Hispanic White (NHW), 30.3% (95% CI = 28.3% to 32.3%) among non-Hispanic Black (NHB), 21.8% (95% CI = 19.9% to 23.7%) among Hispanic, and 17.7% (95% CI = 14.1% to 21.3%) among Asian and Pacific Islander men in 2012. The absolute screening frequency declined by 9.5% from 2012 to 2018, with a larger decline among NHB (11.6%) than NHW men (9.3%). The relative annual decrease was greater among NHB (OR = 0.86, 95% CI = 0.84 to 0.88) than NHW men (OR = 0.89, 95% CI = 0.89 to 0.90; Pheterogeneity = .005), driven by a larger decline among NHB men ages 40-54 years. The NHB to NHW IRR for total prostate cancer increased from 1.73 (95% CI = 1.69 to 1.76) in 2011 to 1.87 (95% CI = 1.83 to 1.92) in 2012 and has remained elevated, driven by differences in localized tumor incidence. Metastatic disease incidence is rising across all racial and ethnic groups.The frequency of prostate cancer screening varies by race and ethnicity, and there was a modestly steeper decline in PSA testing among younger NHB men relative to NHW men since 2012. The NHB to NHW IRR for localized prostate cancer modestly increased following 2012.
A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)
Authors: Hannah Choe, Nirav N. Shah, Patrice Chevallier, Marie Thérèse Rubio, Mark A. Schroeder, Nancy M. Hardy, Patrick J. Stiff, Carlos Solano, Ibrahim Yakoub-Agha, Jonathan A. Gutman, Scott D. Rowley, Maria Caterina Mico', Elisabetta Terruzzi, Rafael F. Duarte, Rodica Morariu-Zamfir, Michael Arbushites, Kai Ding, Miguel-Angel Perales
Journal: Blood (2020)
A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results
Authors: Junyuan Qi, Jian Li, Bin Jiang, Bo Jiang, Hongzhong Liu, Xinxin Cao, Meixiang Zhang, Yuan Meng, Xiaoyu MA, Yingmin Jia, Jiyuan Guo, Yanni Zhang, Wei Huang, Jianxiang Wang
Journal: Blood (2020)
Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
Authors: David Hughes, Radhika Jhaveri, Bhavesh Shah, Frances Blevins, Alexamil Rodriguez, Shayna Sarosiek, Adam Lerner, John Mark Sloan, Vaishali Sanchorawala
Journal: Blood (2020)
Abstract 279: A Defective Mechanosensing Promotes Impaired Fibroblast-to-myofibroblast Maturation in the Aging Mouse Heart
Authors: Aude Angelini, JoAnn Trial, Katarzyna A Cieslik
Journal: Circulation Research (2020)

In the aging heart, fibroblasts have a reduced ability to mature into myofibroblasts (expressing contractile actin a-SMA), which is necessary for scar contraction in wound healing. The mechanosensing pathway bridges the extracellular matrix (ECM) with the actin cytoskeleton and is altered during aging. We emphasize that changes in this pathway may affect myofibroblast activation. Using various methods (mass spectrometry, qPCR, flow, IF staining, and western), we found several abnormalities in the fibroblasts derived from old mouse hearts: 1) ECM deposited was altered with an increased quantity of collagens and the presence of fibronectin variant Anastellin that opposes myofibroblast maturation; 2) there was a 50% reduction of Kindlin-2, a protein that promotes integrin activation; 3) Polymerized (F-) to monomeric (G-) actin ratio was decreased by 65%, possibly due to a 5-fold increase in pERKs1/2 level, a negative regulator of F-actin; and pERKs inhibition (by 2.5μM, PD-0325901) increased by 2-fold F/G actin ratio; 4) we found an increased cytoplasmic retention of MRTF-A (by 44%), an actin-sensitive co-transcription factor (necessary for a-SMA) that shuttles into the nucleus in response to F-actin formation; 5) pERKs inhibition increased a-SMA transcription by 78%. Thus, the disrupted mechanosensing pathway contributes to the impaired myofibroblast maturation in the aging heart. All experiments were performed in young (3-4 month-old) and old (24-30 month-old) hearts or primary cardiac fibroblasts isolated from male C57BL/6J mice. Unpaired Student’s t-test was used for statistical analysis, n=2 for mass spectrometry and n=4-10 for all other biological repeats.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study
Authors: Max Lataillade, Jacob P Lalezari, Michael Kozal, Judith A Aberg, Gilles Pialoux, Pedro Cahn, Melanie Thompson, Jean-Michel Molina, Santiago Moreno, Beatriz Grinsztejn, Ricardo S Diaz, Antonella Castagna, Princy N Kumar, Gulam H Latiff, Edwin De Jesus, Marcia Wang, Shiven Chabria, Margaret Gartland, Amy Pierce, Peter Ackerman, Cyril Llamoso
Journal: The Lancet HIV (2020)
Hodgkin Lymphoma Reed-Sternberg Cells Induce Immunosuppressive and Pro-Angiogenic Phenotype of Tumor-Associated Macrophages in a Paracrine Manner
Authors: Maciej Szydlowski, Michał Pawlak, Filip Garbicz, Patryk Górniak, Justyna Żurańska, Magdalena Król, Bartłomiej Taciak, Maciej Białasek, Anna Szumera-Ciećkiewicz, Kamil Sokół, Monika Stańczak, Daria Owczarek, Monika Prochorec-Sobieszek, Anna Polak, Emilia Bialopiotrowicz, Michał Kurlapski, Jan Zaucha, Paweł Wołkow, Przemyslaw Juszczynski
Journal: Blood (2020)
Phenotypic and Functional Characterization of Multiple Myeloma By Single Cell Mass Cytometry (CyTOF)
Authors: Linda B Baughn, Erik Jessen, Matthew Smith, Neeraj Sharma, Joselle Cook, Surendra Dasari, Kathryn E. Pearce, Nathalie Meurice, Michael A. Linden, A. Keith Stewart, P. Leif Bergsagel, Brian G. Van Ness, Shaji K. Kumar
Journal: Blood (2020)
Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer
Authors: Jinyang Li, Salina Yuan, Robert J. Norgard, Fangxue Yan, Yu H. Sun, Il-Kyu Kim, Allyson J. Merrell, Yogev Sela, Yanqing Jiang, Natarajan V. Bhanu, Benjamin A. Garcia, Robert H. Vonderheide, Andrés Blanco, Ben Z. Stanger
Journal: Cancer Discovery (2020)

Abstract Although immunotherapy has revolutionized cancer care, patients with pancreatic ductal adenocarcinoma (PDA) rarely respond to these treatments, a failure that is attributed to poor infiltration and activation of T cells in the tumor microenvironment (TME). We performed an in vivo CRISPR screen and identified lysine demethylase 3A (KDM3A) as a potent epigenetic regulator of immunotherapy response in PDA. Mechanistically, KDM3A acts through Krueppel-like factor 5 (KLF5) and SMAD family member 4 (SMAD4) to regulate the expression of the epidermal growth factor receptor (EGFR). Ablation of KDM3A, KLF5, SMAD4, or EGFR in tumor cells altered the immune TME and sensitized tumors to combination immunotherapy, whereas treatment of established tumors with an EGFR inhibitor, erlotinib, prompted a dose-dependent increase in intratumoral T cells. This study defines an epigenetic–transcriptional mechanism by which tumor cells modulate their immune microenvironment and highlights the potential of EGFR inhibitors as immunotherapy sensitizers in PDA. Significance: PDA remains refractory to immunotherapies. Here, we performed an in vivo CRISPR screen and identified an epigenetic–transcriptional network that regulates antitumor immunity by converging on EGFR. Pharmacologic inhibition of EGFR is sufficient to rewire the immune microenvironment. These results offer a readily accessible immunotherapy-sensitizing strategy for PDA. This article is highlighted in the In This Issue feature, p. 521
Autophagy Inhibition Enhances CDK4/6 Inhibitor-Induced Apoptosis in t(8;21) Acute Myeloid Leukemia Cells
Authors: Kana Nakatani, Hidemasa Matsuo, Yutarou Harata, Moe Higashitani, Asami Koyama, Mina Noura, Yoko Nishinaka-Arai, Yasuhiko Kamikubo, Souichi Adachi
Journal: Blood (2020)
In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors
Authors: Steven W. Pipe, Michael Recht, Michael U. Callaghan, Robert F. Sidonio, Jerry Grandoni, Veronique Duretz, Daniel Bonzo, Jean Luc Plantier, Sean Evans, Ian S Mitchell, Cedric Hermans
Journal: Blood (2020)
Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
Authors: Yingbing Wang, Karen L. Ayres, Debra A. Goldman, Maura N. Dickler, Aditya Bardia, Ingrid A. Mayer, Eric Winer, Jill Fredrickson, Carlos L. Arteaga, José Baselga, Henry C. Manning, Umar Mahmood, Gary A. Ulaner
Journal: Clinical Cancer Research (2019)

In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.
RE: How the Coronavirus Disease-2019 May Improve Care: Rethinking Cervical Cancer Prevention
Authors: Cheryl R Clark, Jennifer S Haas, Stephenie C Lemon, Karen M Freund, Karen Burns White, Caylin Marotta, Amy J Wint, Amy M LeClair, Christine Lloyd-Travaglini, Victoria Xiao, Nicole Casanova, Tracy A Battaglia
Journal: JNCI Journal of the National Cancer Institute (2020)

These past months of the coronavirus disease-2019 (COVID-2019) pandemic have given us ample opportunity to reflect on the US health-care system. Despite overwhelming tragedy, it is an opportunity for us to learn and to change. As we postpone routine visits because of the pandemic, we worry about risks for patients who delay cancer screening. We use cervical cancer screening and prevention as an example of how we can use some lessons learned from the pandemic to prevent collateral losses, such as an increase in cancers. COVID-2019-related health-system changes, like the more rapid evaluation of diagnostic tests and vaccines, the transition to compensated virtual care for most counseling and education visits, and broadened access to home services, offer potential benefits to the delivery of cervical cancer screening and prevention. While we detail the case for cervical cancer prevention, many of the issues discussed are generalizable to other preventative measures. It would be a tragedy if the morbidity and mortality of COVID-2019 are multiplied because of additional suffering caused by delayed or deferred cancer screening and diagnostic evaluation-but maybe with creativity and reflection, we can use this pandemic to improve care.
Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review
Authors: Houssein Safa, Monica Tamil, Philippe E Spiess, Brandon Manley, Julio Pow-Sang, Scott M Gilbert, Firas Safa, Brian D Gonzalez, Laura B Oswald, Adele Semaan, Adi Diab, Jad Chahoud
Journal: JNCI Journal of the National Cancer Institute (2020)

Patient-reported outcomes (PROs) promote patient centeredness in clinical trials; however, in the field of rapidly emerging and clinically impressive immunotherapy, data on PROs are limited.